Breaking News

Gallus BioPharma Appoints Quality & Regulatory VP

By Kristin Brooks | February 12, 2014

Kile brings 27 years of industry experience

Claudette Kile has been appointed vice president of Quality & Regulatory at Gallus BioPharmaceuticals to support the company’s growth of its contract manufacturing services. Ms. Kile will be responsible for the planning, implementation and daily operations of the Quality & Regulatory organization at Gallus headquarters in St. Louis and the Princeton, NJ facility.
Ms. Kile has 27 years of industry experience in medical devices, biologics, and pharmaceuticals, with specialized expertise in building global compliant quality systems. Most recently, she was senior director of quality at Jazz Pharmaceuticals, where she led the oversight of global clinical trials and drug safety and pharmacovigilance activities. Previously she held roles in quality at Emergent Biosolutions, where she oversaw the supply of vaccines and antibody therapy products from preclinical through commercial, as well as managed her own consultancy focused on regulatory affairs, compliance, and quality assurance.
“Gallus has a strong track record in process development, clinical and commercial manufacturing of licensed biopharmaceuticals at both sites, and the addition of Claudette Kile to our team strengthens our commitment to maintaining exemplary compliance for our pharma and biotech clients as their products mature through the clinic towards licensure,” said Mark Bamforth, president and chief executive officer of Gallus.

Related Contract Manufacturing:

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research